An evaluation of the tolerability and feasibility of combining 5-Amino-Levulinic Acid (5-ALA) with carmustine wafers (Gliadel) in the surgical management of primary Glioblastoma (GALA-5 Trial)
Phase of Trial: Phase II
Latest Information Update: 09 Oct 2017
At a glance
- Drugs Aminolevulinic acid (Primary) ; Carmustine polifeprosan 20 wafer (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions
- Acronyms GALA-5
- 16 Feb 2016 Status changed from active, no longer recruiting to completed, according to ISRCTN: Current Controlled Trials record.
- 07 Dec 2015 Planned primary completion date changed from 1 May 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov record.
- 22 Jun 2013 Accrual to date is 105% according to United Kingdom Clinical Research Network.